These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 38551727)
1. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay. Hashimoto T; Nakamura Y; Oki E; Kobayashi S; Yuda J; Shibuki T; Bando H; Yoshino T Int J Clin Oncol; 2024 May; 29(5):495-511. PubMed ID: 38551727 [TBL] [Abstract][Full Text] [Related]
2. Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment. Widman AJ; Shah M; Frydendahl A; Halmos D; Khamnei CC; Øgaard N; Rajagopalan S; Arora A; Deshpande A; Hooper WF; Quentin J; Bass J; Zhang M; Langanay T; Andersen L; Steinsnyder Z; Liao W; Rasmussen MH; Henriksen TV; Jensen SØ; Nors J; Therkildsen C; Sotelo J; Brand R; Schiffman JS; Shah RH; Cheng AP; Maher C; Spain L; Krause K; Frederick DT; den Brok W; Lohrisch C; Shenkier T; Simmons C; Villa D; Mungall AJ; Moore R; Zaikova E; Cerda V; Kong E; Lai D; Malbari MS; Marton M; Manaa D; Winterkorn L; Gelmon K; Callahan MK; Boland G; Potenski C; Wolchok JD; Saxena A; Turajlic S; Imielinski M; Berger MF; Aparicio S; Altorki NK; Postow MA; Robine N; Andersen CL; Landau DA Nat Med; 2024 Jun; 30(6):1655-1666. PubMed ID: 38877116 [TBL] [Abstract][Full Text] [Related]
3. Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patients. Frydendahl A; Nors J; Rasmussen MH; Henriksen TV; Nesic M; Reinert T; Afterman D; Lauterman T; Kuzman M; Gonzalez S; Glavas D; Smadback J; Maloney D; Levativ J; Yahalom M; Ptashkin R; Tavassoly I; Donenhirsh Z; White E; Kandasamy R; Alon U; Nordentoft I; Lindskrog SV; Dyrskjøt L; Jaensch C; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Zviran A; Oklander B; Andersen CL Eur J Cancer; 2024 Nov; 211():114314. PubMed ID: 39316995 [TBL] [Abstract][Full Text] [Related]
4. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670 [TBL] [Abstract][Full Text] [Related]
5. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction. Li X; Liu T; Bacchiocchi A; Li M; Cheng W; Wittkop T; Mendez FL; Wang Y; Tang P; Yao Q; Bosenberg MW; Sznol M; Yan Q; Faham M; Weng L; Halaban R; Jin H; Hu Z EMBO Mol Med; 2024 Sep; 16(9):2188-2209. PubMed ID: 39164471 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Molecular Residual Disease by a Fixed Panel in Resectable Colorectal Cancer. Yang J; Yu C; Li H; Peng D; Zhou Q; Yao J; Lv J; Fang S; Shi J; Wei Y; Wang G; Cai S; Zhang Z; Zhang Z; Zhou J Cancer Res Treat; 2024 Oct; 56(4):1183-1196. PubMed ID: 38726508 [TBL] [Abstract][Full Text] [Related]
7. Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges. Wen X; Coradduzza D; Shen J; Scanu AM; Muroni MR; Massidda M; Rallo V; Carru C; Angius A; De Miglio MR Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893604 [TBL] [Abstract][Full Text] [Related]
8. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Abbosh C; Birkbak NJ; Swanton C Nat Rev Clin Oncol; 2018 Sep; 15(9):577-586. PubMed ID: 29968853 [TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis. Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376 [TBL] [Abstract][Full Text] [Related]
10. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments. Oh Y; Yoon SM; Lee J; Park JH; Lee S; Hong T; Chung LI; Sudhaman S; Riddell T; Palsuledesai CC; Krainock M; Liu MC; Chae YK Thorac Cancer; 2024 May; 15(13):1095-1102. PubMed ID: 38558374 [TBL] [Abstract][Full Text] [Related]
11. Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan. Sato S; Nakamura Y; Oki E; Yoshino T Clin Colorectal Cancer; 2023 Mar; 22(1):53-58. PubMed ID: 36567192 [TBL] [Abstract][Full Text] [Related]
12. Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer. Ryoo SB; Heo S; Lim Y; Lee W; Cho SH; Ahn J; Kang JK; Kim SY; Kim HP; Bang D; Kang SB; Yu CS; Oh ST; Park JW; Jeong SY; Kim YJ; Park KJ; Han SW; Kim TY Br J Cancer; 2023 Aug; 129(2):374-381. PubMed ID: 37280413 [TBL] [Abstract][Full Text] [Related]
13. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases. Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868 [No Abstract] [Full Text] [Related]
14. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment. Parikh AR; Chee BH; Tsai J; Rich TA; Price KS; Patel SA; Zhang L; Ibrahim F; Esquivel M; Van Seventer EE; Jarnagin JX; Raymond VM; Corvera CU; Hirose K; Nakakura EK; Corcoran RB; Van Loon K; Atreya CE Clin Cancer Res; 2024 Jul; 30(14):2964-2973. PubMed ID: 38695832 [TBL] [Abstract][Full Text] [Related]
15. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma. Nordentoft I; Lindskrog SV; Birkenkamp-Demtröder K; Gonzalez S; Kuzman M; Levatic J; Glavas D; Ptashkin R; Smadbeck J; Afterman D; Lauterman T; Cohen Y; Donenhirsh Z; Tavassoly I; Alon U; Frydendahl A; Rasmussen MH; Andersen CL; Lamy P; Knudsen M; Polak P; Zviran A; Oklander B; Agerbæk M; Jensen JB; Dyrskjøt L Eur Urol; 2024 Oct; 86(4):301-311. PubMed ID: 38811314 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection. Lonardi S; Nimeiri H; Xu C; Zollinger DR; Madison RW; Fine AD; Gjoerup O; Rasola C; Angerilli V; Sharma S; Wu HT; Palsuledesai CC; Malhotra M; Aleshin A; Loupakis F; Renkonen E; Hegde P; Fassan M Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232827 [TBL] [Abstract][Full Text] [Related]
17. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919 [TBL] [Abstract][Full Text] [Related]
18. Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study. Slater S; Bryant A; Aresu M; Begum R; Chen HC; Peckitt C; Lazaro-Alcausi R; Carter P; Anandappa G; Khakoo S; Melcher L; Potter V; Marti FM; Huang J; Branagan G; George N; Abulafi M; Duff S; Raja A; Gupta A; West N; Bucheit L; Rich T; Chau I; Cunningham D; Starling N; Clin Cancer Res; 2024 Aug; 30(16):3459-3469. PubMed ID: 38864835 [TBL] [Abstract][Full Text] [Related]
19. ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine. Pellini B; Pejovic N; Feng W; Earland N; Harris PK; Usmani A; Szymanski JJ; Qaium F; Mudd J; Petty M; Jiang Y; Singh A; Maher CA; Henke LE; Park H; Ciorba MA; Kim H; Mutch MG; Pedersen KS; Tan BR; Hawkins WG; Fields RC; Chaudhuri AA JCO Precis Oncol; 2021; 5():. PubMed ID: 34250420 [TBL] [Abstract][Full Text] [Related]
20. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review). Chen H; Zhou Q Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]